Warfarin

Warfarinum

For medical students2 min readUpdated 2026-10-10

Warfarin is an indirect anticoagulant and a coumarin derivative. It inhibits blood coagulation by blocking vitamin K-dependent metabolic processes and is widely used for the prevention of thromboembolic events.

Pharmacological classAgents affecting the blood system (vitamin K antagonists / indirect anticoagulants).

MetabolismMicrosomal oxidation in the liver (cytochrome P-450 system, predominantly CYP2C9).

Dosage formsTablets 1–10 mg.

Half-life30 to 60 hours (depending on the stereoisomer).

Mechanism of Action and Metabolism

Warfarin is a racemic mixture of R- and S-enantiomers, with the S-isomer possessing 4 to 5 times greater anticoagulant activity. The drug undergoes extensive microsomal oxidation in the liver. The CYP2C9 isoenzyme plays a key role by metabolizing the S-isomer. Genetic polymorphism of this enzyme is the primary cause of interindividual differences in therapy sensitivity.

Drug Interactions

Warfarin has a narrow therapeutic index, making it highly susceptible to interactions:

Protein binding displacement: Sulfonamides displace warfarin from albumin binding sites (99% bound), sharply increasing free active drug concentration and bleeding risk.
Enzyme inhibition: Drugs such as cimetidine, macrolides, and azole antifungals inhibit CYP3A4/3A5 isoenzymes, slowing warfarin metabolism.
Enzyme induction: Rifampin and phenobarbital accelerate metabolism, reducing the therapeutic effect.

Clinical Significance

The primary risk of warfarin therapy is massive hemorrhage resulting from a critical decrease in blood coagulation. Clinicians must account for dietary factors (e.g., cruciferous vegetables can affect enzyme activity) and concurrent therapies capable of altering the drug's pharmacokinetics.

Administration Guidelines

The drug is administered orally in doses of 1–10 mg. When titrating the dose, monitoring coagulation parameters and accounting for the patient's CYP2C9 genetic status are critical.

Mnemonic

Warfarin — "War" (wages war on clots to keep blood fluid), but "Far" (pharmacokinetics) depends on CYP2C9: if the enzyme is "asleep" (polymorphism), the dose becomes toxic.

Frequently asked questions

Which laboratory parameters are monitored during warfarin dose titration?

Prothrombin time (PT) and the International Normalized Ratio (INR) are monitored during warfarin dose titration. PT and INR assess the extrinsic coagulation pathway and are used to monitor warfarin therapy. INR monitoring is mandatory during warfarin therapy. When HAS-BLED scores are ≥ 3, rigorous laboratory and clinical monitoring is required due to a high risk of bleeding.

What is the exact mechanism of vitamin K's influence on the action of indirect anticoagulants?

The mechanism involves indirect anticoagulants blocking the enzymes that regenerate reduced vitamin K, depleting stores of its active form. Normally, the vitamin K cycle includes:

Hydroquinone — the active form acting as a cofactor in the $\gamma$-carboxylation of coagulation factors (II, VII, IX, X).
Epoxide — the inactive form generated during carboxylation.

Anticoagulants inhibit vitamin K epoxide reductase and DT-diaphorase, preventing the conversion of the epoxide back to hydroquinone. As a result, the synthesis of functional coagulation factors capable of binding calcium is impaired.

Why are sulfonamides dangerous when taking warfarin?

Sulfonamides displace warfarin from plasma protein binding sites, dramatically increasing the concentration of free, active anticoagulant and leading to an increased risk of bleeding.

Which cytochrome P-450 isoenzyme is most important for the metabolism of the S-enantiomer of warfarin?

The CYP2C9 isoenzyme. Its genetic polymorphism determines the patient's individual sensitivity to the drug.

What happens when hepatic microsomal enzymes are induced during warfarin therapy?

The metabolism and inactivation of warfarin are accelerated, leading to a weakened anticoagulant effect.

Go deeper

Impact of CYP2C9 genetic polymorphism on dosing.
Comparative profile of direct and indirect anticoagulants.
Role of vitamin K in the mechanism of action of coumarin derivatives.
Patient management strategies in anticoagulant overdose.
Warfarin interactions with dietary products (grapefruit juice, vitamin K-rich foods).